FEMY stock news · Femasys Inc.
Get alerts for FEMY
Follow Femasys Inc. (FEMY) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for FEMYFemasys Inc. has named John Moorhead to its Board of Directors starting October 30, 2026.
NeutralFemasys added John Moorhead to its board, bringing marketing and product experience. The announcement reports no new business result or trial update, so it does not change the company's outlook.
12 health care companies are changing a lot before the market opens on Tuesday.
NeutralFemasys shares rose about 13% before Tuesday's open, but the article gives no company news explaining the move. It does not change the company's business outlook.
12 health care companies are changing prices before the market opens on Wednesday.
NeutralThe article reports FEMY rose 10.15% to $2.82 in pre-market trading, but it gives no company news, so the report does not change how we read FEMY.
FDA grants Femasys a new regulatory pathway for its non-invasive contraceptive solution.
NeutralFemasys has received FDA authorization for a new pathway for its FemBloc contraceptive device, which could streamline the approval process and enhance its market potential. This regulatory milestone is expected to positively influence investor sentiment and stock performance.
Femasys Inc secures a significant definitive agreement (FEMY).
NeutralFemasys Inc has filed a Form 8-K indicating its entry into a material definitive agreement, which is likely to create new opportunities for the company and positively influence its market standing.